Biocon Sept qtr PAT seen down 14% at Rs 77cr: Dolat Capital

22932 Investors following Biocon. Share this News with them.

0

Like this story, share it with millions of investors on M3

Biocon Sept qtr PAT seen down 14% at Rs 77cr: Dolat Capital

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Biocon September quarter net sales are expected to go down by 30.1% at Rs 475 crore, year-on-year, (YoY) basis.

Post your opinion here

 

0

Tweet

Share on Tumblr

ALSO READ News and Notices about Biocon See interviews with Biocon Management See what other Experts & Brokerages are saying about Biocon See previous Results of Biocon

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Biocon September quarter net sales are expected to go down by 30.1% at Rs 475 crore, year-on-year, (YoY) basis. Notably, the estimated sales in Sep'11 quarter do not include revenues from Axicorp (divested earlier).

The company's net profit is expected to go down by 14% at Rs 76.5 crore on YoY basis.